| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medicine, Medical University of South Carolina and the Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29425;
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110;
Department of Pathology, University of Miami School of Medicine, Miami, FL 33125; and
Department of Medicine, University of Colorado Health Science Center, Denver, CO 80262
Complement activation and tissue deposition of complement fragments occur during disease progression in lupus nephritis. Genetic deficiency of some complement components (e.g., Factor B) and infusion of complement inhibitors (e.g., Crry, anti-C5 Ab) protect against inflammatory renal disease. Paradoxically, genetic deficiencies of early components of the classical complement pathway (e.g., C1q, C4, and C2) are associated with an increased incidence of lupus in humans and lupus-like disease in murine knockout strains. Complement protein C3 is the converging point for activation of all three complement pathways and thus plays a critical role in biologic processes mediated by complement activation. To define the role of C3 in lupus nephritis, mice rendered C3 deficient by targeted deletion were backcrossed for eight generations to MRL/lpr mice, a mouse strain that spontaneously develops lupus-like disease. We derived homozygous knockout (C3-/-), heterozygous (C3+/-), and C3 wild-type (C3+/+) MRL/lpr mice. Serum levels of autoantibodies and circulating immune complexes were similar among the three groups. However, there was earlier and significantly greater albuminuria in the C3-/- mice compared with the other two groups. Glomerular IgG deposition was also significantly greater in the C3-/- mice than in the other two groups, although overall pathologic renal scores were similar. These results indicate that C3 and/or activation of C3 is not required for full expression of immune complex renal disease in MRL/lpr mice and may in fact play a beneficial role via clearance of immune complexes.
This article has been cited by other articles:
|
|
 |
|
  X. Wu, D. Spitzer, D. Mao, S. L. Peng, H. Molina, and J. P. Atkinson Membrane Protein Crry Maintains Homeostasis of the Complement System J. Immunol., August 15, 2008; 181(4): 2732 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Brownlie, K. E. Lawlor, H. A. Niederer, A. J. Cutler, Z. Xiang, M. R. Clatworthy, R. A. Floto, D. R. Greaves, P. A. Lyons, and K. G.C. Smith Distinct cell-specific control of autoimmunity and infection by Fc{gamma}RIIb J. Exp. Med., April 14, 2008; 205(4): 883 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice J. Immunol., January 15, 2008; 180(2): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miwa, M. A. Maldonado, L. Zhou, K. Yamada, G. S. Gilkeson, R. A. Eisenberg, and W.-C. Song Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent Mechanisms Am. J. Pathol., April 1, 2007; 170(4): 1258 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Dong, Q-X Wang, C-Y Zhou, X-F Ma, and Y-C Zhang Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice Lupus, February 1, 2007; 16(2): 101 - 109. [Abstract] [PDF]
|
|
|
|
|
|
H. Sekine, K. L. Graham, S. Zhao, M. K. Elliott, P. Ruiz, P. J. Utz, and G. S. Gilkeson Role of MHC-Linked Genes in Autoantigen Selection and Renal Disease in a Murine Model of Systemic Lupus Erythematosus J. Immunol., November 15, 2006; 177(10): 7423 - 7434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Alexander, O.G.B. Aneziokoro, A. Chang, B. K. Hack, A. Markaryan, A. Jacob, R. Luo, M. Thirman, M. Haas, and R. J. Quigg Distinct and Separable Roles of the Complement System in Factor H-Deficient Bone Marrow Chimeric Mice with Immune Complex Disease J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Sheerin, K. Abe, P. Risley, and S. H. Sacks Accumulation of Immune Complexes in Glomerular Disease Is Independent of Locally Synthesized C3 J. Am. Soc. Nephrol., March 1, 2006; 17(3): 686 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Wenderfer, B. Ke, T. J. Hollmann, R. A. Wetsel, H. Y. Lan, and M. C. Braun C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr Mice J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3572 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, I. Osawe, M. Haas, and R. J. Quigg Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis J. Immunol., August 1, 2005; 175(3): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, M. C. Pickering, M. Haas, I. Osawe, and R. J. Quigg Complement Factor H Limits Immune Complex Deposition and Prevents Inflammation and Scarring in Glomeruli of Mice with Chronic Serum Sickness J. Am. Soc. Nephrol., January 1, 2005; 16(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. K. Zhang, S. Gallant, I. Molano, O. M. Moussa, P. Ruiz, D. D. Spyropoulos, D. K. Watson, and G. Gilkeson Decreased Expression of the Ets Family Transcription Factor Fli-1 Markedly Prolongs Survival and Significantly Reduces Renal Disease in MRL/lpr Mice J. Immunol., November 15, 2004; 173(10): 6481 - 6489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R L Rubin, M Teodorescu, E H Beutner, and R W Plunkett Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus Lupus, April 1, 2004; 13(4): 249 - 256. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Quigg Complement and the Kidney J. Immunol., October 1, 2003; 171(7): 3319 - 3324. [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, M. Haas, D. M. Kraus, B. K. Hack, J. K. Rakstang, V. M. Holers, and R. J. Quigg Administration of a Soluble Recombinant Complement C3 Inhibitor Protects Against Renal Disease in MRL/lpr Mice J. Am. Soc. Nephrol., March 1, 2003; 14(3): 670 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miwa, M. A. Maldonado, L. Zhou, X. Sun, H. Y. Luo, D. Cai, V. P. Werth, M. P. Madaio, R. A. Eisenberg, and W.-C. Song Deletion of Decay-Accelerating Factor (CD55) Exacerbates Autoimmune Disease Development in MRL/lpr Mice Am. J. Pathol., September 1, 2002; 161(3): 1077 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, V. M. Holers, S. A. Boackle, and C. M. Blatteis Modulation of Mouse Endotoxic Fever by Complement Infect. Immun., May 1, 2002; 70(5): 2519 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, M. Haas, S. A. Boackle, D. M. Kraus, P. N. Cunningham, P. Park, J. J. Alexander, R. K. Anderson, K. Culhane, V. M. Holers, et al. Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice J. Immunol., April 1, 2002; 168(7): 3601 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mitchell, M. C. Pickering, J. Warren, L. Fossati-Jimack, J. Cortes-Hernandez, H. T. Cook, M. Botto, and M. J. Walport C1q Deficiency and Autoimmunity: The Effects of Genetic Background on Disease Expression J. Immunol., March 1, 2002; 168(5): 2538 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Einav, O. O. Pozdnyakova, M. Ma, and M. C. Carroll Complement C4 Is Protective for Lupus Disease Independent of C3 J. Immunol., February 1, 2002; 168(3): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
